KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons. PMID 39928572 · Clin Infect Dis · 2026-Feb-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo. PMID 41608890 · J Am Heart Assoc · 2026-Feb-03 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identifying Locally Recurrent Versus Second Primary Breast Cancer: Genomic Versus Clinical Criteria from Carolina Breast Cancer Study Phase III. PMID 41324404 · Cancer Epidemiol Biomarkers Prev · 2026-Feb-03 This is a genomic classification study from the Carolina Breast Cancer Study Phase III cohort. It is a human, oncology, Phase III study with original results, but it is not randomized, has no drug intervention, and its primary endpoints are diagnostic accuracy metrics for classifying tumor recurrence vs. second primary, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the inclusion criteria for a drug-containing, randomized, Phase III/IIIb or Phase II/III trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial. PMID 41205146 · JAMA · 2026-Feb-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial. PMID 41701495 · JAMA Netw Open · 2026-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials. PMID 41684244 · J Antimicrob Chemother · 2026-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. PMID 41676981 · J Antimicrob Chemother · 2026-Feb-02 Study is a Phase IV randomized controlled trial of an antiretroviral regimen for HIV infection, not oncology. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) is reported. Primary outcome is 'treatment failure' defined by virological failure, discontinuation, or loss to follow-up, which is not a standard oncology time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Self-Acupressure for Fatigue in Patients Surviving Ovarian Cancer: A Randomized Clinical Trial. PMID 41642626 · JAMA Netw Open · 2026-Feb-02 Study is a randomized, phase 3 trial in human ovarian cancer survivors, but the intervention is self-acupressure (non-drug), and the primary efficacy endpoint is change in fatigue score (not a time-to-event endpoint like OS, PFS, DFS, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study. PMID 41630017 · BMC Med · 2026-Feb-02 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it fails the critical time-to-event endpoint criterion. The primary endpoint is an incidence measure, not a time-to-event outcome. While survival was a secondary endpoint, the results do not include Kaplan-Meier survival analyses or hazard ratios, and the abstract only states no difference in survival without providing the necessary time-to-event evidence.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase III triple-blind randomised placebo-controlled trial to evaluate effectiveness of early treatment with pregabalin to reduce pain severity after whiplash road traffic injury: study protocol for the PRioRTI Trial {1}. PMID 41629976 · Trials · 2026-Feb-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Fecal incontinence after prostate cancer irradiation: a systematic literature review. PMID 41629638 · Prostate Cancer Prostatic Dis · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial. PMID 41629265 · Signal Transduct Target Ther · 2026-Feb-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol. PMID 41628935 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study. PMID 41628919 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial. PMID 41266255 · J Nucl Med · 2026-Feb-02 The study is a human oncology Phase 3 randomized trial with original results. However, it is ineligible because the intervention is a diagnostic/imaging procedure (PSMA-targeted PET/MRI-guided biopsy) with no drug-containing therapeutic intervention, and the primary outcomes are diagnostic accuracy metrics (sensitivity, specificity, PPV, NPV) rather than time-to-event efficacy endpoints.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. PMID 40929381 · Eur Heart J Cardiovasc Pharmacother · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. PMID 41738096 · Am J Respir Crit Care Med · 2026-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluation of oncologic safety and clinical effectiveness of immediate autologous fat grafting in breast-conserving surgery: a multicenter, prospective, randomized controlled clinical trial for breast cancer. PMID 41731868 · Int J Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. PMID 41661214 · JAMA Neurol · 2026-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex. PMID 41642149 · J Drugs Dermatol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT). PMID 41621028 · Qual Life Res · 2026-Feb-01 The record describes a methodological sub-study embedded within the Phase 3 MOTION trial. It does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial. The analysis focuses on defining responder thresholds for non-time-to-event clinical outcome assessments.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer. PMID 41620988 · Qual Life Res · 2026-Feb-01 The record is a formal result of a randomized trial (KEYNOTE-590) with a drug intervention and a primary/key secondary time-to-event endpoint (OS, PFS). However, the specific analysis reported is a secondary, pre-specified health-related quality of life (Q-TWiST) analysis, which is not a primary efficacy endpoint per the eligibility criteria. The publication type 'Randomized Controlled Trial' does not confirm Phase III/IIIb or Phase II/III status, but the trial is a large, definitive randomized study. The analysis itself is a secondary endpoint analysis focused on quality of life, making it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intrathecal Morphine for Enhanced Recovery After Laparoscopic Colorectal Surgery: A Randomized Clinical Trial. PMID 41433024 · JAMA Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial. PMID 41411005 · JAMA Ophthalmol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. PMID 41379459 · JAMA Oncol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. PMID 41343184 · JAMA Otolaryngol Head Neck Surg · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. PMID 41343176 · JAMA Oncol · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Portable Transcranial Electrical Stimulation and Internet-Based Behavioral Therapy for Major Depression Study (PSYLECT): Results of the maintenance phase. PMID 41284536 · J Affect Disord · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials. PMID 41224012 · J Affect Disord · 2026-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. PMID 41189315 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Elective versus involved target volume definition of stereotactic spine radiosurgery for spinal metastases: A phase II randomized clinical trial. PMID 41143555 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen. PMID 41081774 · J Acquir Immune Defic Syndr · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial. PMID 41037024 · AIDS · 2026-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study. PMID 41033612 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial. PMID 40876576 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 The trial meets criteria for oncology, human, randomized, and phase 3, and reports primary results. However, it is ineligible because the intervention is a non-drug hydrogel, and the primary endpoint is a dosimetric measure, not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial. PMID 40367489 · Am J Gastroenterol · 2026-Feb-01 The record is excluded because it does not meet the 'drug intervention' and 'time_to_event' criteria. The study compares procedural techniques (snare-tip vs. ESD knife) for endoscopic resection of colorectal polyps, which is a non-drug intervention. The primary efficacy endpoint (en bloc resection rate) is not a time-to-event outcome. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ligation site of the inferior mesenteric vein in laparoscopic radical resection of rectal cancer: a study protocol for a multicenter randomized-controlled trial. PMID 42147431 · Gastroenterol Rep (Oxf) · 2026-Feb 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis. PMID 41964430 · Immunotherapy · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. PMID 41949135 · Indian J Med Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. PMID 41883885 · Cureus · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. PMID 41859618 · Cureus · 2026-Feb 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. PMID 41853582 · Res Pract Thromb Haemost · 2026-Feb This is a retrospective cohort study (non-randomized) of direct oral anticoagulants in pediatric oncology patients. While it is oncology, human, and reports original results on a drug intervention, it lacks the required randomized controlled trial design (Phase III/IIIb or II/III) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The primary endpoints are safety (bleeding) and efficacy (recurrent thrombosis), which are event rates, not time-to-event outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review. PMID 41822639 · Cureus · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era. PMID 41809424 · Gastroenterol Rep (Oxf) · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Interim analysis of short-term outcomes between robotic and laparoscopic surgery for colon cancer: results from the ESSIMIC trial. PMID 41802309 · Ann Coloproctol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Evaluating the Effect of Acceptance and Commitment Therapy on Post-traumatic Growth in Cancer Survivors: A Pilot Non-randomized Controlled Trial in a Greek Sample. PMID 41798432 · Cureus · 2026-Feb The study is a non-randomized, pilot trial of a psychotherapy intervention for cancer survivors. It does not meet the core criteria of being a randomized trial of a drug intervention with a time-to-event primary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ethical considerations in randomization for neurosurgical oncology trials: A scoping review. PMID 41798128 · Neurooncol Pract · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial. PMID 41768988 · EClinicalMedicine · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis. PMID 41731962 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Interim Results from a Randomized Trial. PMID 41726013 · Indian J Surg Oncol · 2026-Feb The trial is oncology, human, randomized, and includes a drug intervention, but it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary outcome is pCR, and distant metastasis is reported as a count, not a time-to-event. Phase is not definitively established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -